{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:57:22Z","timestamp":1789001842470,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Emerging evidence highlights a complex interconnection between metabolic dysfunction and chronic inflammation in psoriatic arthritis (PsA), positioning glucose and lipid abnormalities not only as comorbidities but as active contributors to disease pathogenesis. In fact, rather than being incidental findings, conditions such as insulin resistance, atherogenic dyslipidemia, and visceral obesity interact with the immune system, amplifying inflammatory circuits and promoting joint and systemic damage. This review delves into the metabolic dimension of PsA, shedding light on how pro-inflammatory cytokines and adipokine imbalances reshape glucose and lipid homeostasis. Special attention is given to molecular pathways, such as impaired insulin signaling and altered lipid uptake, that link systemic inflammation to cardiometabolic risk. Furthermore, we examine the impact of these metabolic alterations in clinical practice and how antirheumatic therapies might improve metabolic balance and promote long-term cardiovascular protective effects. By unraveling these interactions, we aim to provide new insights into the clinical management of PsA and underscore the need for integrated therapeutic strategies that address both inflammation and metabolic health.<\/jats:p>","DOI":"10.1007\/s00592-025-02565-5","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T06:44:47Z","timestamp":1755153887000},"page":"1831-1841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Metabolic challenges of glucose and lipid dysregulation in psoriatic arthritis: a narrative review from pathogenesis to clinical practice"],"prefix":"10.1007","volume":"62","author":[{"given":"Mauro","family":"Fatica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ferrigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneida","family":"\u00c7ela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"D\u2019Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Conigliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Cardellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-1729","authenticated-orcid":false,"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2565_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.berh.2016.10.001","volume":"30","author":"PH Dessein","year":"2016","unstructured":"Dessein PH, Solomon A, Hollan I (2016) Metabolic abnormalities in patients with inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 30:901\u2013915. https:\/\/doi.org\/10.1016\/j.berh.2016.10.001","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2565_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40744-023-00535-3","volume":"10","author":"E Lubrano","year":"2023","unstructured":"Lubrano E, Scriffignano S, Fatica M et al (2023) Psoriatic arthritis in males and females: differences and similarities. Rheumatol Ther 10:589\u2013599. https:\/\/doi.org\/10.1007\/s40744-023-00535-3","journal-title":"Rheumatol Ther"},{"key":"2565_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/metabo15030206","volume":"15","author":"M Radi\u0107","year":"2025","unstructured":"Radi\u0107 M, Belan\u010di\u0107 A, \u0110oga\u0161 H et al (2025) Cardiometabolic risk in psoriatic arthritis: a hidden burden of inflammation and metabolic dysregulation. Metabolites 15:206. https:\/\/doi.org\/10.3390\/metabo15030206","journal-title":"Metabolites"},{"key":"2565_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1172\/JCI10934","volume":"107","author":"L Rui","year":"2001","unstructured":"Rui L, Aguirre V, Kim JK et al (2001) Insulin\/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 107:181\u2013189. https:\/\/doi.org\/10.1172\/JCI10934","journal-title":"J Clin Invest"},{"key":"2565_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1126\/science.271.5249.665","volume":"271","author":"GS Hotamisligil","year":"1996","unstructured":"Hotamisligil GS, Peraldi P, Budavari A et al (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665\u2013668. https:\/\/doi.org\/10.1126\/science.271.5249.665","journal-title":"Science"},{"key":"2565_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.bbrc.2008.07","volume":"374","author":"J Ye","year":"2008","unstructured":"Ye J (2008) Regulation of PPARgamma function by TNF-alpha. Biochem Biophys Res Commun 374:405\u2013408. https:\/\/doi.org\/10.1016\/j.bbrc.2008.07","journal-title":"Biochem Biophys Res Commun"},{"key":"2565_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/s1359-6101(03)00052-2","volume":"14","author":"H Ruan","year":"2003","unstructured":"Ruan H, Lodish HF (2003) Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 14:447\u2013455. https:\/\/doi.org\/10.1016\/s1359-6101(03)00052-2","journal-title":"Cytokine Growth Factor Rev"},{"key":"2565_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1615\/CritRevEukaryotGeneExpr.2017019712","volume":"27","author":"K Rehman","year":"2017","unstructured":"Rehman K, Akash MSH, Liaqat A et al (2017) Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr 27:229\u2013236. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2017019712","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"2565_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrendo.2009.271","volume":"6","author":"T Mandrup-Poulsen","year":"2010","unstructured":"Mandrup-Poulsen T, Pickersgill L, Donath MY (2010) Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 6:158\u2013166. https:\/\/doi.org\/10.1038\/nrendo.2009.271","journal-title":"Nat Rev Endocrinol"},{"key":"2565_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4331\/wjbc.v11.i3.76","volume":"11","author":"T Wang","year":"2020","unstructured":"Wang T, Wang J, Hu X et al (2020) Current understanding of glucose transporter 4 expression and functional mechanisms. World J Biol Chem 11:76\u201398. https:\/\/doi.org\/10.4331\/wjbc.v11.i3.76","journal-title":"World J Biol Chem"},{"key":"2565_CR11","doi-asserted-by":"publisher","unstructured":"Kalwat MA, Scheuner D, Rodrigues-Dos-Santos K, et al. (2021) The pancreatic \u00df-cell response to secretory demands and adaption to stress. Endocrinology 162:bqab173. https:\/\/doi.org\/10.1210\/endocr\/bqab173","DOI":"10.1210\/endocr\/bqab173"},{"key":"2565_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1590\/s0004-27302012000900001","volume":"56","author":"G Paz-Filho","year":"2012","unstructured":"Paz-Filho G, Mastronardi C, Franco CB et al (2012) Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arq Bras Endocrinol Metabol 56:597\u2013607. https:\/\/doi.org\/10.1590\/s0004-27302012000900001","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"2565_CR13","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/1756-185X.12444","volume":"19","author":"O Dikbas","year":"2016","unstructured":"Dikbas O, Tosun M, Bes C et al (2016) Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. Int J Rheum Dis 19:672\u2013677. https:\/\/doi.org\/10.1111\/1756-185X.12444","journal-title":"Int J Rheum Dis"},{"key":"2565_CR14","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1111\/febs.15322","volume":"287","author":"D Tripathi","year":"2020","unstructured":"Tripathi D, Kant S, Pandey S et al (2020) Resistin in metabolism, inflammation, and disease. FEBS J 287:3141\u20133149. https:\/\/doi.org\/10.1111\/febs.15322","journal-title":"FEBS J"},{"key":"2565_CR15","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1136\/annrheumdis-2012-202325","volume":"72","author":"L Eder","year":"2013","unstructured":"Eder L, Jayakar J, Pollock R et al (2013) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis 72:1956\u20131961. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202325","journal-title":"Ann Rheum Dis"},{"key":"2565_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3899\/jrheum.160861","volume":"44","author":"L Eder","year":"2017","unstructured":"Eder L, Chandran V, Cook R et al (2017) The risk of developing diabetes mellitus in patients with psoriatic arthritis: a cohort study. J Rheumatol 44:286\u2013291. https:\/\/doi.org\/10.3899\/jrheum.160861","journal-title":"J Rheumatol"},{"key":"2565_CR17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/14712598.2024.2384090","volume":"24","author":"F Caso","year":"2024","unstructured":"Caso F, Fatica M, Ferraioli M et al (2024) The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in psoriatic arthritis. Expert Opin Biol Ther 24:719\u2013731. https:\/\/doi.org\/10.1080\/14712598.2024.2384090","journal-title":"Expert Opin Biol Ther"},{"key":"2565_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/1744666X.2020.1740593","volume":"16","author":"F Caso","year":"2020","unstructured":"Caso F, Chimenti MS, Navarini L et al (2020) Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. Expert Rev Clin Immunol 16:409\u2013420. https:\/\/doi.org\/10.1080\/1744666X.2020.1740593","journal-title":"Expert Rev Clin Immunol"},{"key":"2565_CR19","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1080\/14712598.2022.2152321","volume":"22","author":"F Sunzini","year":"2022","unstructured":"Sunzini F, D\u2019Antonio A, Fatica M et al (2022) What\u2019s new and what\u2019s next for biological and targeted synthetic treatments in psoriatic arthritis? Expert Opin Biol Ther 22:1545\u20131559. https:\/\/doi.org\/10.1080\/14712598.2022.2152321","journal-title":"Expert Opin Biol Ther"},{"key":"2565_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/sj.bjp.0707259","volume":"151","author":"J Li","year":"2007","unstructured":"Li J, Zhang N, Ye B et al (2007) Non-steroidal anti-inflammatory drugs increase insulin release from beta cells by inhibiting ATP-sensitive potassium channels. Br J Pharmacol 151:483\u2013493. https:\/\/doi.org\/10.1038\/sj.bjp.0707259","journal-title":"Br J Pharmacol"},{"key":"2565_CR21","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.3390\/jcm11113186","volume":"11","author":"MH Lin","year":"2022","unstructured":"Lin MH, Wu WT, Chen YC et al (2022) Association between non-steroidal anti-inflammatory drugs use and the risk of type 2 diabetes mellitus: a nationwide retrospective cohort study. J Clin Med 11:3186. https:\/\/doi.org\/10.3390\/jcm11113186","journal-title":"J Clin Med"},{"key":"2565_CR22","doi-asserted-by":"publisher","first-page":"7965","DOI":"10.4081\/dr.2019.7965","volume":"11","author":"T Dehpouri","year":"2019","unstructured":"Dehpouri T, Rokni GR, Narenjbon NA et al (2019) Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: a pilot study. Dermatol Reports 11:7965. https:\/\/doi.org\/10.4081\/dr.2019.7965","journal-title":"Dermatol Reports"},{"key":"2565_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/tcrm.s130666","volume":"13","author":"HH Chen","year":"2017","unstructured":"Chen HH, Chen DY, Lin CC et al (2017) Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis\/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. Ther Clin Risk Manag 13:583\u2013592. https:\/\/doi.org\/10.2147\/tcrm.s130666","journal-title":"Ther Clin Risk Manag"},{"key":"2565_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.735150","volume":"8","author":"F Atzeni","year":"2021","unstructured":"Atzeni F, Gerratana E, Francesco Masala I et al (2021) Psoriatic arthritis and metabolic syndrome: is there a role for disease modifying anti-rheumatic drugs? Front Med (Lausanne) 8:735150. https:\/\/doi.org\/10.3389\/fmed.2021.735150","journal-title":"Front Med (Lausanne)"},{"key":"2565_CR25","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1210\/jc.2010-1170","volume":"96","author":"TL Stanley","year":"2011","unstructured":"Stanley TL, Zanni MV, Johnsen S et al (2011) TNF-antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 96:e146-150. https:\/\/doi.org\/10.1210\/jc.2010-1170","journal-title":"J Clin Endocrinol Metab"},{"key":"2565_CR26","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1001\/jama.2011.878","volume":"305","author":"DH Solomon","year":"2011","unstructured":"Solomon DH, Massarotti E, Garg R et al (2011) Association between diseasemodifying anti-rheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 305:2525\u20132531. https:\/\/doi.org\/10.1001\/jama.2011.878","journal-title":"JAMA"},{"key":"2565_CR27","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/rheumatology\/keab474","volume":"61","author":"LD Ferguson","year":"2022","unstructured":"Ferguson LD, Cathcart S, Rimmer D et al (2022) Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the immune metabolic associations in psoriatic arthritis study. Rheumatol (Oxf) 61:1026\u20131034. https:\/\/doi.org\/10.1093\/rheumatology\/keab474","journal-title":"Rheumatol (Oxf)"},{"key":"2565_CR28","doi-asserted-by":"publisher","first-page":"1245535","DOI":"10.3389\/fphar.2023.1245535","volume":"14","author":"D Collotta","year":"2023","unstructured":"Collotta D, Franchina MP, Carlucci V et al (2023) Recent advances in JAK inhibitors for the treatment of metabolic syndrome. Front Pharmacol 14:1245535. https:\/\/doi.org\/10.3389\/fphar.2023.1245535","journal-title":"Front Pharmacol"},{"key":"2565_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103819","volume":"24","author":"SG Tsiogkas","year":"2025","unstructured":"Tsiogkas SG, Gkouvi A, Kontouli KM et al (2025) Janus kinase inhibitors for psoriatic arthritis: evidence from a systematic review and network meta-analysis. Autoimmun Rev 24:103819. https:\/\/doi.org\/10.1016\/j.autrev.2025.103819","journal-title":"Autoimmun Rev"},{"key":"2565_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103357","volume":"22","author":"CG Gialouri","year":"2023","unstructured":"Gialouri CG, Pappa M, Evangelatos G et al (2023) Effect of body mass index on treatment response of biologic\/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review. Autoimmun Rev 22:103357. https:\/\/doi.org\/10.1016\/j.autrev.2023.103357","journal-title":"Autoimmun Rev"},{"key":"2565_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.bbalip.2017.02.005","volume":"1862","author":"E Makoveichuk","year":"2017","unstructured":"Makoveichuk E, Vorrsj\u00f6 E, Olivecrona T et al (2017) TNF-\u03b1 decreases lipoprotein lipase activity in 3T3-L1 adipocytes by up-regulation of angiopoietin-like protein 4. Biochim Biophys Acta Mol Cell Biol Lipids 1862:533\u2013540. https:\/\/doi.org\/10.1016\/j.bbalip.2017.02.005","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2565_CR32","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1210\/jc.2004-0603","volume":"89","author":"ME Trujillo","year":"2004","unstructured":"Trujillo ME, Sullivan S, Harten I et al (2004) Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 89:5577\u20135582. https:\/\/doi.org\/10.1210\/jc.2004-0603","journal-title":"J Clin Endocrinol Metab"},{"key":"2565_CR33","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65:1038\u20131048. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012","journal-title":"Metabolism"},{"key":"2565_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.929078","volume":"9","author":"Q Wang","year":"2022","unstructured":"Wang Q, Wang Y, Xu D (2022) Research progress on Th17 and T regulatory cells and their cytokines in regulating atherosclerosis. Front Cardiovasc Med 9:929078. https:\/\/doi.org\/10.3389\/fcvm.2022.929078","journal-title":"Front Cardiovasc Med"},{"key":"2565_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172578","volume":"134","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Kulkarni NN, Takahashi T et al (2024) Increased LL37 in psoriasis and other inflammatory disorders promotes LDL uptake and atherosclerosis. J Clin Invest 134:e172578. https:\/\/doi.org\/10.1172\/JCI172578","journal-title":"J Clin Invest"},{"key":"2565_CR36","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2119\/molmed.2010.00004","volume":"16","author":"K Yin","year":"2010","unstructured":"Yin K, Liao DF, Tang CK (2010) ATP-binding membrane cassette transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport. Mol Med 16:438\u2013449. https:\/\/doi.org\/10.2119\/molmed.2010.00004","journal-title":"Mol Med"},{"key":"2565_CR37","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1136\/ard.59.11.904","volume":"59","author":"SM Jones","year":"2000","unstructured":"Jones SM, Harris CP, Lloyd J et al (2000) Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 59:904\u2013909. https:\/\/doi.org\/10.1136\/ard.59.11.904","journal-title":"Ann Rheum Dis"},{"key":"2565_CR38","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cmet.2022.09.020","volume":"34","author":"M Metz","year":"2022","unstructured":"Metz M, Beghini M, Wolf P et al (2022) Leptin increases hepatic triglyceride export via a vagal mechanism in humans. Cell Metab 34:1719-1731.e5. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.020","journal-title":"Cell Metab"},{"key":"2565_CR39","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","volume":"158","author":"V Azzu","year":"2020","unstructured":"Azzu V, Vacca M, Virtue S et al (2020) Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology 158:1899\u20131912. https:\/\/doi.org\/10.1053\/j.gastro.2019.12.054","journal-title":"Gastroenterology"},{"key":"2565_CR40","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.2337\/db05-1322","volume":"55","author":"MJ Yoon","year":"2006","unstructured":"Yoon MJ, Lee GY, Chung JJ et al (2006) Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 55:2562\u20132570. https:\/\/doi.org\/10.2337\/db05-1322","journal-title":"Diabetes"},{"key":"2565_CR41","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3390\/ijms20051190","volume":"20","author":"H Yanai","year":"2019","unstructured":"Yanai H, Yoshida H (2019) Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives. Int J Mol Sci 20:1190. https:\/\/doi.org\/10.3390\/ijms20051190","journal-title":"Int J Mol Sci"},{"key":"2565_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","volume":"41","author":"S Gupta","year":"2021","unstructured":"Gupta S, Syrimi Z, Hughes DM et al (2021) Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 41:275\u2013284. https:\/\/doi.org\/10.1007\/s00296-020-04775-2","journal-title":"Rheumatol Int"},{"key":"2565_CR43","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/1756-185X.14147","volume":"24","author":"A Loganathan","year":"2021","unstructured":"Loganathan A, Kamalaraj N, El-Haddad C et al (2021) Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis. Int J Rheum Dis 24:1112\u20131120. https:\/\/doi.org\/10.1111\/1756-185X.14147","journal-title":"Int J Rheum Dis"},{"key":"2565_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40744-022-00502-4","volume":"10","author":"B Li","year":"2023","unstructured":"Li B, Huang H, Zhao J et al (2023) Discrepancy in metabolic syndrome between psoriatic arthritis and rheumatoid arthritis: a direct comparison of two cohorts in one center. Rheumatol Ther 10:135\u2013148. https:\/\/doi.org\/10.1007\/s40744-022-00502-4","journal-title":"Rheumatol Ther"},{"key":"2565_CR45","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","volume":"7","author":"A Kumthekar","year":"2020","unstructured":"Kumthekar A, Ogdie A (2020) Obesity and psoriatic arthritis: a narrative review. Rheumatol Ther 7:447\u2013456. https:\/\/doi.org\/10.1007\/s40744-020-00215-6","journal-title":"Rheumatol Ther"},{"key":"2565_CR46","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","volume":"74","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V et al (2015) Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 74:813\u2013817. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204448","journal-title":"Ann Rheum Dis"},{"key":"2565_CR47","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/brv.12178","volume":"91","author":"FW Sanders","year":"2016","unstructured":"Sanders FW, Griffin JL (2016) De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc 91:452\u2013468. https:\/\/doi.org\/10.1111\/brv.12178","journal-title":"Biol Rev Camb Philos Soc"},{"key":"2565_CR48","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1210\/me.2008-0464","volume":"23","author":"C Xu","year":"2009","unstructured":"Xu C, He J, Jiang H et al (2009) Direct effect of glucocorticoids on lipolysis in adipocytes. Mol Endocrinol 23:1161\u20131170. https:\/\/doi.org\/10.1210\/me.2008-0464","journal-title":"Mol Endocrinol"},{"key":"2565_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/bcpt.12244","volume":"115","author":"AM Schjerning Olsen","year":"2014","unstructured":"Schjerning Olsen AM, Fosb\u00f8l EL, Gislason GH (2014) The impact of NSAID treatment on cardiovascular risk\u2014insight from Danish observational data. Basic Clin Pharmacol Toxicol 115:179\u2013184. https:\/\/doi.org\/10.1111\/bcpt.12244","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2565_CR50","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard-2024-225534","volume":"83","author":"A Kerschbaumer","year":"2024","unstructured":"Kerschbaumer A, Smolen JS, Ferreira RJO et al (2024) Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 83:760\u2013774. https:\/\/doi.org\/10.1136\/ard-2024-225534","journal-title":"Ann Rheum Dis"},{"key":"2565_CR51","doi-asserted-by":"publisher","unstructured":"Karmacharya P, Ogdie A, Eder L (2021) Psoriatic arthritis and the association with cardiometabolic disease: a narrative review. Ther Adv Musculoskelet Dis 13:1759720X21998279. https:\/\/doi.org\/10.1177\/1759720X21998279","DOI":"10.1177\/1759720X21998279"},{"key":"2565_CR52","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/art.22447","volume":"56","author":"N Sattar","year":"2007","unstructured":"Sattar N, Crompton P, Cherry L et al (2007) Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 56:831\u2013839. https:\/\/doi.org\/10.1002\/art.22447","journal-title":"Arthritis Rheum"},{"key":"2565_CR53","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3390\/jcm12051934","volume":"12","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E et al (2023) Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis. J Clin Med 12:1934. https:\/\/doi.org\/10.3390\/jcm12051934","journal-title":"J Clin Med"},{"key":"2565_CR54","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/acr.23930","volume":"71","author":"DD Gladman","year":"2019","unstructured":"Gladman DD, Charles-Schoeman C, McInnes IB et al (2019) Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase iii and long-term extension studies. Arthritis Care Res (Hoboken) 71:1387\u20131395. https:\/\/doi.org\/10.1002\/acr.23930","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2565_CR55","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.3390\/jcm11236894","volume":"11","author":"A Makris","year":"2022","unstructured":"Makris A, Barkas F, Sfikakis PP et al (2022) The effect of upadacitinib on lipid profile and cardiovascular events: a meta-analysis of randomized controlled trials. J Clin Med 11:6894. https:\/\/doi.org\/10.3390\/jcm11236894","journal-title":"J Clin Med"},{"key":"2565_CR56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/life14030395","volume":"14","author":"P Guerra","year":"2024","unstructured":"Guerra P, Di Cesare A, Rosi E et al (2024) Effects on lipid profile after one year of apremilast therapy in patients with psoriasis: a monocentric experience. Life (Basel) 14:395. https:\/\/doi.org\/10.3390\/life14030395","journal-title":"Life (Basel)"},{"key":"2565_CR57","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/ar3915","volume":"14","author":"CM Bartels","year":"2012","unstructured":"Bartels CM, Saucier JM, Thorpe CT et al (2012) Monitoring diabetes in patients with and without rheumatoid arthritis: a medicare study. Arthritis Res Ther 14:R166. https:\/\/doi.org\/10.1186\/ar3915","journal-title":"Arthritis Res Ther"},{"key":"2565_CR58","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/580404","volume":"2013","author":"J Dreiher","year":"2013","unstructured":"Dreiher J, Freud T, Cohen AD (2013) Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract 2013:580404. https:\/\/doi.org\/10.1155\/2013\/580404","journal-title":"Dermatol Res Pract"},{"key":"2565_CR59","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee (2025) 2 diagnosis and classification of diabetes: standards of care in diabetes-2025. Diabet Care 48(Supplement_1):S27-S49. https:\/\/doi.org\/10.2337\/dc25-S002","DOI":"10.2337\/dc25-S002"},{"key":"2565_CR60","doi-asserted-by":"publisher","unstructured":"Authors\/Task Force Members; Ryd\u00e9n L, Grant PJ, et al. (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the european society of cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035\u20133087. https:\/\/doi.org\/10.1093\/eurheartj\/eht108","DOI":"10.1093\/eurheartj\/eht108"},{"key":"2565_CR61","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.amepre.2014.05.012","volume":"47","author":"S Chung","year":"2014","unstructured":"Chung S, Azar KM, Baek M et al (2014) Reconsidering the age thresholds for type II diabetes screening in the U.S. Am J Prev Med 47:375\u2013381. https:\/\/doi.org\/10.1016\/j.amepre.2014.05.012","journal-title":"Am J Prev Med"},{"key":"2565_CR62","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12933-024-02334-8","volume":"23","author":"M Duan","year":"2024","unstructured":"Duan M, Zhao X, Li S et al (2024) Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001\u20132018. Cardiovasc Diabetol 23:243. https:\/\/doi.org\/10.1186\/s12933-024-02334-8","journal-title":"Cardiovasc Diabetol"},{"key":"2565_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 76:17\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209775","journal-title":"Ann Rheum Dis"},{"key":"2565_CR64","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","volume":"5","author":"M Sampson","year":"2020","unstructured":"Sampson M, Ling C, Sun Q et al (2020) A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia. JAMA Cardiol 5:540\u2013548. https:\/\/doi.org\/10.1001\/jamacardio.2020.0013","journal-title":"JAMA Cardiol"},{"key":"2565_CR65","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"2565_CR66","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","unstructured":"SCORE2 working group and ESC Cardiovascular risk collaboration (2021) SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 42:2439\u20132454. https:\/\/doi.org\/10.1093\/eurheartj\/ehab309","journal-title":"Eur Heart J"},{"key":"2565_CR67","doi-asserted-by":"publisher","unstructured":"SCORE2-OP working group and ESC Cardiovascular risk collaboration (2021) SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 42:2455\u20132467. https:\/\/doi.org\/10.1093\/eurheartj\/ehab312","DOI":"10.1093\/eurheartj\/ehab312"},{"key":"2565_CR68","doi-asserted-by":"publisher","unstructured":"(2023) SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 44(28):2544\u20132556. https:\/\/doi.org\/10.1093\/eurheartj\/ehad260","DOI":"10.1093\/eurheartj\/ehad260"},{"key":"2565_CR69","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3390\/jpm14121114","volume":"14","author":"M Fatica","year":"2024","unstructured":"Fatica M, \u00c7ela E, Ferraioli M et al (2024) The effects of smoking, alcohol, and dietary habits on the progression and management of spondyloarthritis. J Pers Med 14:1114. https:\/\/doi.org\/10.3390\/jpm14121114","journal-title":"J Pers Med"},{"key":"2565_CR70","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","volume":"72","author":"N Duru","year":"2013","unstructured":"Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905\u20131913. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203249","journal-title":"Ann Rheum Dis"},{"key":"2565_CR71","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40744-023-00574-w","volume":"10","author":"E Lubrano","year":"2023","unstructured":"Lubrano E, Scriffignano S, Perrotta FM (2023) Difficult to treat and refractory to treatment in psoriatic arthritis. Rheumatol Ther 10:1119\u20131125. https:\/\/doi.org\/10.1007\/s40744-023-00574-w","journal-title":"Rheumatol Ther"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-025-02565-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:08:44Z","timestamp":1764180524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-025-02565-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":71,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["2565"],"URL":"https:\/\/doi.org\/10.1007\/s00592-025-02565-5","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}